

Merck Pipeline

2Q2025 Reflecting Pipeline to April 30, 2025

Lead-in language

The chart below reflects the company's research pipeline as of **April 30, 2025**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer, immunology and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.

Being developed in a collaboration.


Being developed in combination with Keytruda Being developed as monotherapy and/or in combination with Keytruda

Moved forward since last pipeline update.

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Melanoma Ovarian Pancreas Prostate patritumab deruxtecan MK-1022 ^{1,3}	Alzheimer's MK-1167	Cancer NSCLC quavonlimab MK-1308 ²	Cancer Biliary Bladder Breast Cervical CRC Endometrial HCC HNSCC Melanoma Ovarian Pancreas ifinatamab deruxtecan MK-2400	Cancer Biliary Bladder CRC Neoplasm Malignant Pancreatic sacituzumab tirumotecan MK-2870 ^{1,3}
Cancer Advanced Solid Tumors Prostate KEYTRUDA® MK-3475	Cancer Cutaneous Squamous Cell Heme subcutaneous pembrolizumab MK-3475A	PH-COPD MK-5475	Cancer Biliary Bladder Cervical CRC Endometrial Gastric Ovarian Pancreas Renal SCLC raludotatug deruxtecan MK-5909 ¹	MASH efinopegdutide MK-6024



- . Being developed in a collaboration.
- 2. Being developed in combination with Keytruda
- 3. Being developed as monotherapy and/or in combination with Keytruda



Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Immunology Lupus Vitiligo MK-6194	lmmunology Systemic Sclerosis tulisokibart MK-7240	Pulmonary Hypertension due to Left Heart Disease WINREVAIR™ MK-7962	HIV-1 PrEP MK-8527	HIV-1 Infection islatravir+MK-8507 MK-8591B
Dengue Fever Virus Vaccine V181	Cancer Bladder RCC intismeran autogene V940^{1, 2}			



- Being developed in a collaboration.
- . Being developed in combination with Keytruda
- 3. Being developed as monotherapy and/or in combination with Keytruda
- 4. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials
- 5. Available in the U.S. under Emergency Use Authorization
- 6. Program is in a Phase 2/3 study

Moved forward since last pipeline update.

Phase 3	Phase 3	Phase 3	Phase 3	Phase 3
Hypercholesterolemia enlicitide decanoate MK-0616	Cancer NSCLC patritumab deruxtecan MK-1022¹ (EU)	Cancer Heme nemtabrutinib MK-1026	Cancer NSCLC MK-1084 ²	Cancer RCC quavonlimab + pembrolizumab MK-1308A
Cancer Heme zilovertamab vedotin MK-2140	Cancer Esophageal SCLC ifinatamab deruxtecan MK-2400 ¹	Cancer Breast Cervical Endometrial Gastric NSCLC Ovarian sacituzumab tirumotecan MK-2870 ^{1,3}	Diabetic Macular Edema MK-3000⁶	Cancer Hepatocellular (EU) Ovarian SCLC KEYTRUDA® MK-3475
Cancer Myeloproliferative Disorders bomedemstat MK-3543	Anti-Viral COVID-19 LAGEVRIO® MK-4482^{1,5} (US)	Cancer Prostate opevesostat MK-5684	Immunology Crohn's Disease Ulcerative Colitis tulisokibart MK-7240	Cancer NSCLC SCLC LYNPARZA® MK-7339 ^{1,2}
Cancer Esophageal LENVIMA® MK-7902 ^{1, 2}	HIV-1 Infection doravirine + islatravir MK-8591A ⁴	HIV-1 Infection islatravir+lenacapavir MK-8591D ^{1,4}	Cancer Melanoma NSCLC intismeran autogene V940^{1,2}	



. Being developed in a collaboration

 In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working with Daiichi Sankyo to address FDA feedback.




Moved forward since last pipeline update.

New Molecular Entities Under Review	New Molecular Entities Under Review	New Molecular Entities Under Review
Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC (HERTHENA-Lung01) patritumab deruxtecan MK-1022 1,2 (US)	Respiratory Syncytial Virus clesrovimab MK-1654 (US, EU)	Previously Approved Solid Tumors subcutaneous pembrolizumab MK-3475A (US, EU)
von Hippel-Lindau (VHL) Disease (LITESPARK-004) Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-005) WELIREG® MK-6482 (JPN)	Pulmonary Arterial Hypertension (STELLAR) WINREVAIR™ MK-7962 (JPN)	Pneumococcal Vaccine Adult CAPVAXIVE™ V116 (JPN)

Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review
Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KN689) KEYTRUDA® MK-3475 (US, JPN)	1L Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (KN483) KEYTRUDA® MK-3475 (JPN)
Advanced, Unresectable, or Metastatic Pheochromocytoma and Paraganglioma (PPGL) (LITESPARK-015) WELIREG® MK-6482 (US)	





New Molecular EntitiesApprovals¹

Bacterial Infection ZERBAXA MK-7625A (CHN)

Pneumococcal Vaccine
Adult
CAPVAXIVETM
V116
(EU)

Certain SupplementalApprovals¹

1L Unresectable Non Epithelioid Malignant Plural Mesothelioma (KN483) KEYTRUDA® MK-3475 (EU)

> HPV Vaccine Males (16-26 yo) GARDASIL9® V503 (CHN)

Forward-looking statement

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

No duty to update

The information contained in the presentation set forth below was current as of April 30, 2025. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after April 30, 2025.

The chart reflects the Merck research pipeline as of April 30, 2025.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.